Intellia Therapeutics
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell NTLA and other ETFs, options, and stocks.About NTLA
Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases.
CEOJohn M. Leonard
CEOJohn M. Leonard
Employees403
Employees403
HeadquartersCambridge, Massachusetts
HeadquartersCambridge, Massachusetts
Founded2014
Founded2014
Employees403
Employees403
NTLA Key Statistics
Market cap1.23B
Market cap1.23B
Price-Earnings ratio-2.29
Price-Earnings ratio-2.29
Dividend yield—
Dividend yield—
Average volume4.63M
Average volume4.63M
High today$12.20
High today$12.20
Low today$11.31
Low today$11.31
Open price$12.13
Open price$12.13
Volume3.45M
Volume3.45M
52 Week high$28.18
52 Week high$28.18
52 Week low$5.90
52 Week low$5.90
NTLA News
Simply Wall St 6d
Possible Bearish Signals With Intellia Therapeutics Insiders Disposing StockIntellia Therapeutics, Inc. ( ) shareholders might have a reason to worry after multiple insiders sold their shares over the last year. When analyzing insider t...
Analyst ratings
76%
of 29 ratingsBuy
75.9%
Hold
20.7%
Sell
3.4%
People also own
Based on the portfolios of people who own NTLA. This list is generated using Robinhood data, and it’s not a recommendation.